Dr. Gabriel Michael Danovitch, MD

Dr. Danovitch practices at Ronald Reagan UCLA Medical Center in Los Angeles, California, part of University of California Health.

Dr. Danovitch's NPI, 1750307864, was assigned on July 14, 2006. Dr. Danovitch graduated from Barts and The London SOM & Dent in 1968. Dr. Danovitch holds California license A34636.

Dr. Danovitch's primary practice is Ronald Reagan UCLA Medical Center, at 757 Westwood Plaza, Los Angeles, CA 90095 in Los Angeles County. The practice phone is (310) 825-6301.

Dr. Danovitch's primary practice is Ronald Reagan UCLA Medical Center in Los Angeles, California, part of University of California Health. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Danovitch to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Danovitch practices, 2 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Danovitch's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Danovitch is board certified in internal medicine by the American Board of Internal Medicine. Dr. Danovitch is licensed in California.

Dmand AI lists chronic kidney disease among the conditions Dr. Danovitch treats.

CMS data shows 209 Medicare services from Dr. Danovitch across 2 procedure codes in 2024, for 107 Medicare patients. Medicare paid $18,168 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 107 Medicare patients who saw Dr. Danovitch in 2024. The largest group is under 65, with 49 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 50% are also on Medicaid. Their average risk score is 6.38, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Danovitch's median patient age at 57, with 43% women.

In 2024, Dr. Danovitch wrote 123 Medicare Part D claims for 41 patients. 86% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $67 in total drug cost. In 2023, CMS named 139 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Danovitch for performance year 2024, reported as part of a group.

Dmand AI links 20 papers to Dr. Danovitch, published from 2011 to 2020. 2020 was the busiest year, with 5. The most frequent topics are Kidney Transplantation. Dr. Danovitch's most frequent co-authors are Suphamai Bunnapradist, MD, Francis Leo Delmonico, MD and Erik Lawrence Lum, MD.

Dmand AI links Dr. Danovitch to 1 clinical trial.

CMS Open Payments shows 18 general payments to Dr. Danovitch from 8 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 84% of the total. Mallinckrodt Enterprises LLC paid the most, $8,081.

Dmand AI lists 4 awards for Dr. Danovitch, most recently CMS Stage 1 EHR in 2013.

Dr. Danovitch graduated from Barts and The London SOM & Dent in 1968.

Dr. Danovitch is in network with 9 carriers, including Elevance, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.